Immunis Inc., a pioneering clinical-stage biotechnology company focused on developing stem cell-derived secretome therapies, has successfully raised $25 million in its latest funding round. This substantial investment aims to propel the company's mission of addressing one of the most pressing health challenges of our time: age-related diseases and immune dysfunction. The funding will primarily support the ongoing Phase 1/2a clinical trial of IMMUNA, Immunis’ investigational secretome designed to combat sarcopenia—age-related muscle wasting that affects all individuals as they age. By harnessing a balanced blend of all-natural, clinical-grade factors, IMMUNA seeks to refine immune cell responses, significantly improving muscle mass, regeneration, and function, as evidenced by recent pre-clinical studies published in GeroScience and Aging Cell.
With FDA approval for a Phase II trial to investigate IMMUNA’s potential benefits in reversing sarcopenic obesity, Immunis is poised to tackle not only the muscle loss associated with aging but also the rising obesity rates that have become a growing concern for the elderly. As Chairman Dr. Keirstead highlights, "Our innovative therapy shows promising results by simultaneously decreasing fat and enhancing muscle," underscoring the dual-action potential of their treatment. The funds raised will enhance Immunis' capabilities to advance its clinical trials and further research, reinforcing its commitment to improving mobility and overall quality of life for millions afflicted by age-related health issues. As the company moves forward, it remains dedicated to creating solutions that empower individuals to maintain a robust, healthy life as they age.
